UnitedHealth Group Incorporated (UNH) Stake Lessened by Cambridge Trust Co.
Cambridge Trust Co. lowered its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH) by 3.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 151,043 shares of the healthcare conglomerate’s stock after selling 4,954 shares during the quarter. UnitedHealth Group comprises approximately 1.9% of Cambridge Trust Co.’s investment portfolio, making the stock its 13th largest holding. Cambridge Trust Co.’s holdings in UnitedHealth Group were worth $28,007,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of UNH. Harbour Capital Advisors LLC increased its holdings in UnitedHealth Group by 18,383.4% in the 2nd quarter. Harbour Capital Advisors LLC now owns 2,516,706 shares of the healthcare conglomerate’s stock worth $13,573,000 after buying an additional 2,503,090 shares during the period. State Street Corp increased its holdings in UnitedHealth Group by 2.5% in the 1st quarter. State Street Corp now owns 45,724,509 shares of the healthcare conglomerate’s stock worth $7,499,276,000 after buying an additional 1,122,534 shares during the period. Ameriprise Financial Inc. increased its holdings in UnitedHealth Group by 29.9% in the 1st quarter. Ameriprise Financial Inc. now owns 3,332,761 shares of the healthcare conglomerate’s stock worth $546,574,000 after buying an additional 766,573 shares during the period. Swiss National Bank increased its holdings in UnitedHealth Group by 25.8% in the 1st quarter. Swiss National Bank now owns 3,719,488 shares of the healthcare conglomerate’s stock worth $610,033,000 after buying an additional 763,161 shares during the period. Finally, Karp Capital Management Corp acquired a new position in UnitedHealth Group in the 1st quarter worth approximately $113,729,000. Hedge funds and other institutional investors own 86.19% of the company’s stock.
In other UnitedHealth Group news, insider Larry C. Renfro sold 50,574 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $198.11, for a total transaction of $10,019,215.14. Following the sale, the insider now directly owns 195,625 shares in the company, valued at $38,755,268.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gail R. Wilensky sold 5,600 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $199.49, for a total value of $1,117,144.00. Following the sale, the director now owns 60,834 shares in the company, valued at $12,135,774.66. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 76,174 shares of company stock worth $14,981,909. 0.89% of the stock is owned by company insiders.
UNH has been the topic of several research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $205.00 price target on shares of UnitedHealth Group in a report on Friday, July 7th. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price target on shares of UnitedHealth Group in a report on Wednesday, June 28th. BidaskClub upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating in a report on Friday, June 9th. Mizuho set a $235.00 price target on shares of UnitedHealth Group and gave the stock a “buy” rating in a report on Tuesday, July 18th. Finally, Cowen and Company reiterated a “buy” rating on shares of UnitedHealth Group in a report on Friday, July 14th. Three research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $203.59.
UnitedHealth Group Incorporated (NYSE UNH) opened at 200.48 on Thursday. UnitedHealth Group Incorporated has a one year low of $133.03 and a one year high of $200.76. The firm has a 50-day moving average price of $196.09 and a 200-day moving average price of $183.24. The stock has a market cap of $193.84 billion, a price-to-earnings ratio of 24.08 and a beta of 0.63.
UnitedHealth Group (NYSE:UNH) last announced its quarterly earnings data on Tuesday, July 18th. The healthcare conglomerate reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.08. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.32%. The firm had revenue of $50.05 billion for the quarter, compared to analyst estimates of $49.97 billion. During the same quarter in the prior year, the company posted $1.96 earnings per share. UnitedHealth Group’s quarterly revenue was up 7.7% on a year-over-year basis. On average, equities analysts predict that UnitedHealth Group Incorporated will post $9.87 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 19th. Shareholders of record on Friday, September 8th were given a dividend of $0.75 per share. The ex-dividend date was Thursday, September 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.50%. UnitedHealth Group’s payout ratio is 35.13%.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.